These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11157895)

  • 41. Antibiotic prescribing and respiratory tract infections.
    Dahlberg K
    JAMA; 1998 Jan; 279(4):272; author reply 273. PubMed ID: 9450703
    [No Abstract]   [Full Text] [Related]  

  • 42. Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance.
    Cazzola M; Matera MG; Noschese P
    Pulm Pharmacol Ther; 2000; 13(6):249-56. PubMed ID: 11061979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.
    Christ-Crain M; Jaccard-Stolz D; Bingisser R; Gencay MM; Huber PR; Tamm M; Müller B
    Lancet; 2004 Feb; 363(9409):600-7. PubMed ID: 14987884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibiotic kinetic and dynamic attributes for community-acquired respiratory tract infections.
    Nicolau DP
    Am J Manag Care; 2000 Dec; 6(23 Suppl):S1202-10. PubMed ID: 11187444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Refractory respiratory tract infections. 9. Chemotherapy of recent respiratory tract infections. a. Branhamella catarrhalis infection].
    Nagatake T; Rikitomi N; Tao M; Watanabe K; Mbaki N; Matsumoto K
    Nihon Rinsho; 1987 Mar; 45(3):604-10. PubMed ID: 3599486
    [No Abstract]   [Full Text] [Related]  

  • 46. Appropriate antibiotic use in treating respiratory tract infections.
    Poole MD
    Am J Manag Care; 2001 Jun; 7(6 Suppl):S178-82. PubMed ID: 11424586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Managing acute lower respiratory tract infections in an era of antibacterial resistance.
    Volturo GA; Low DE; Aghababian R
    Am J Emerg Med; 2006 May; 24(3):329-42. PubMed ID: 16635707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lower respiratory tract infections in the intensive care unit: consequences of antibiotic resistance for choice of antibiotic.
    Lode H; Schaberg T; Raffenberg M; Mauch H
    Microb Drug Resist; 1995; 1(2):163-7. PubMed ID: 9158751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Do cultures contribute to optimisation of antibiotic therapy in the intensive care unit?
    Schurink CA; Hoitsma M; Rozenberg-Arska M; Joore JC; Hoepelman IM; Bonten MJ
    Int J Antimicrob Agents; 2004 Apr; 23(4):325-31. PubMed ID: 15081079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bacteriological and antibiotic sensitivity test results in 271 cats with respiratory tract infections.
    Schulz BS; Wolf G; Hartmann K
    Vet Rec; 2006 Feb; 158(8):269-70. PubMed ID: 16501159
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections.
    Nicolau D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():61-70. PubMed ID: 12239229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
    Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
    Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance.
    Anzueto A; Norris S
    Int J Antimicrob Agents; 2004 Jul; 24(1):1-17. PubMed ID: 15225854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.
    Langtry HD; Brogden RN
    Drugs; 1997 Jun; 53(6):973-1004. PubMed ID: 9179528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Rational antibiotic therapy of acute upper respiratory tract infections].
    Mazur E
    Pol Merkur Lekarski; 2010 Nov; 29(173):304-8. PubMed ID: 21268914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.